How is Rybrevant administered?

Rybrevant is given as an intravenous (IV) infusion into your vein. Your healthcare provider will administer this medication to you and determine your dose. It may be given alone, in combination with chemotherapy (carboplatin and pemetrexed), or with a kinase inhibitor called Lazcluze (lazertinib) for the treatment of EGFR mutated non-small cell lung cancer (NSCLC).

Patients usually receive this medicine until their cancer worsens or they have side effects that require the drug to be stopped. Your doctor will determine your dose (based on your weight), how many treatments you will receive, and how often you receive them. Depending on your use, you will receive this medicine every 2 or 3 weeks, after initial Rybrevant dosing in the first 6 weeks.

Infusion reactions are common with Rybrevant. You will receive medicines before each dose (called "premedications") to help reduce your risk of an infusion-related reaction. These premedications may include an antihistamine (diphenhydramine), fever-reducer (acetaminophen), and a glucocorticoid (such as dexamethasone).

Symptoms of the infusion-related reaction may include:

• shortness of breath
• flushing
• fever
• chills
• nausea
• chest discomfort
• low blood pressure
• lightheadedness
• vomiting

Tell your doctor right away if you have any of these side effects. Your doctor may need to temporarily stop your infusion, decrease your dose or completely stop your treatment with Rybrevant if you have serious side effects.

Related: Rybrevant side effects (in more detail)

What is Rybrevant used for?

Rybrevant (amivantamab-vmjw) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread in the body or cannot be removed by surgery.

Patients who receive Rybrevant with NSCLC have certain abnormal epidermal growth factor receptor “EGFR” genes identified in a sample of tissue or blood. Your doctor can perform these tests to make sure you can receive Rybrevant. This is called biomarker testing.

There are different types of EGFR mutations, including EGFR exon 19 deletions, EGFR exon 21 L858R substitution mutations, and EGFR exon 20 insertion mutations.

Rybrevant works by attaching to areas on the cancer cell called receptors. By occupying these receptors, it helps to stops the tumors from living, growing, and spreading. Rybrevant also helps the immune system to find and kill cancer cells.

Related questions

• How do Exkivity and Rybrevant compare for NSCLC?
• How does Rybrevant work?
• Is small cell or non-small cell lung cancer worse?

Uses for Rybrevant

• Rybrevant may be used in combination with the oral kinase inhibitor Lazcluze (lazertinib), as a first-line treatment for NSCLC.
• For some patients, Rybrevant may be used in combination with carboplatin and pemetrexed (2 chemotherapy medicines) to treat NSCLC as a second-line agent in patients whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor.
• It may also be used in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC.
• Rybrevant is also used as a single agent (alone) to treat NSCLC in patients whose disease has worsened on or after platinum-based chemotherapy.

Can it be administered at home?

Rybrevant is not normally given at your home. You would typically receive this medicine in a healthcare facility or clinic with appropriate personnel, medicine and equipment so you can be monitored and treated for any infusion-related reactions. Your doctor will tell you when and where you will receive your infusion.

If you miss your appointment, call your healthcare provider as soon as possible to reschedule.

This is not all the information you need to know about Rybrevant (amivantamab-vmjw) for safe and effective use and does not take the place of your healthcare provider's directions. Review the product information and discuss any questions you have with your doctor or other health care provider.